间充质干细胞的免疫调节作用及其在免疫性血小板减少症中的研究进展  

Mesenchymal stem cells:Immunodulatory effects and advances in immune thrombocytopenia

作　　者：唐川惠 文瑞婷 杨志刚 TANG Chuanhui;WEN Ruiting;YANG Zhigang(Department of Hematology,Zhanjiang Central Hospital,Guangdong Medical University,Zhanjiang 524037,China)

机构地区：[1]广东医科大学附属湛江中心医院血液内科,湛江524037

出　　处：《中国免疫学杂志》2025年第3期740-742,750,共4页Chinese Journal of Immunology

基　　金：国家自然科学基金(82200238);广东省自然科学基金(2021A1515010708);湛江市财政资金科技专项竞争性分配项目(2021A05153,2021A05150)。

摘　　要：免疫性血小板减少症(ITP)的发病机制较为复杂,且一线治疗后复发率较高,二线治疗疗效有限,尤其是难治性ITP尚缺乏有效治疗手段。近年研究发现除体液免疫与细胞免疫外,间充质干细胞(MSCs)的功能受损也参与ITP发病。外源性输注MSCs或内源性恢复MSCs的免疫调节功能有望成为ITP的有效治疗策略。因此,本文就MSCs的生物学特性、免疫调节作用及其在ITP中的研究进展进行综述,以期为深入阐明ITP的发病机制、探索ITP的有效治疗方案提供新思路。Pathogenesis of immune thrombocytopenia(ITP)is complex,with a high reoccurence rate after first-line treatment and limited efficacy of second-line treatment,especially in refractory ITP,for which there is a lack of effective treatment.In recent years,it has been found that impaired function of mesenchymal stem cells(MSCs)is also involved in pathogenesis of ITP in addition to humoral and cellular immunity.Exogenous infusion of MSCs or endogenous restoration of immunomodulatory function of MSCs is expected to be an effective treatment strategy for ITP.Therefore,this article reviews biological characteristics and immunomodulatory effects of MSCs and their research progress in ITP,with aim of providing new ideas for further elucidating pathogenesis and exploring effective treatment options of ITP.

关 键 词：免疫性血小板减少症 间充质干细胞 免疫调节 免疫治疗 

分 类 号：R558.2[医药卫生—血液循环系统疾病]